For the fiscal year ending March 2027, net sales have been raised from 63,200 hundred million yen \u2192 64,800 hundred million yen, operating income from 2,000 million yen \u2192 2,400 million yen, ordinary income from 1,400 million yen \u2192 1,800 million yen, and net income attributable to owners of parent from 1,300 million yen \u2192 1,500 million yen. Concurrently, the year-end dividend forecast is increased from 45 yen \u2192 46 yen. The annual dividend is expected to increase from 90 yen \u2192 91 yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4538","jir_company_name":"Fuso Pharmaceutical Industries,Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4538-20261111-01.pdf","jir_short_summary":"For the fiscal year ending March 2027, net sales have been raised from 63,200 hundred million yen \u2192 64,800 hundred million yen, operating income from 2,000 million yen \u2192 2,400 million yen, ordinary income from 1,400 million yen \u2192 1,800 million yen, and net income attributable to owners of parent from 1,300 million yen \u2192 1,500 million yen. Concurrently, the year-end dividend forecast is increased from 45 yen \u2192 46 yen. The annual dividend is expected to increase from 90 yen \u2192 91 yen.","jir_summary":"### Overview of Earnings Guidance Revision\nFuso Pharmaceutical Industries,Ltd. has upwardly revised its full-year earnings guidance for the fiscal year ending March 2027, which was previously announced on May 12, 2026. While first-half sales trends remain firm, price increases in raw materials are expected in the second half. Despite anticipated increases in R&D expenses, the overall outlook is projected to exceed the previous forecast.\n\n### Revision of Dividend Forecast and Shareholder Returns\nThe year-end dividend forecast has been revised from 45 yen per share to 46 yen per share, bringing the annual dividend\u2014including the 45 yen interim dividend\u2014to 91 yen. With a basic policy of strengthening retained earnings and stable dividends and a mid-term management policy aiming for progressive dividends through fiscal 2030, the company will continue to balance investment to reinforce stable supply systems with shareholder returns.","jir_financial_highlights":"Net Sales: 64,800 (Previous forecast 63,200 \u2192 Revised 64,800)\nOperating Income: 2,400 (Previous forecast 2,000 \u2192 Revised 2,400)\nOrdinary Income: 1,800 (Previous forecast 1,400 \u2192 Revised 1,800)\nNet Income Attributable to Owners of Parent: 1,500 (Previous forecast 1,300 \u2192 Revised 1,500)\nNet Income per Share: 175.73 (Previous forecast 152.25 \u2192 Revised 175.73)","jir_category":"","jir_hashtags":"#FusoPharmaceuticalIndustriesLtd, #EarningsGuidanceRevision, #YearEndDividendRevision","jir_key_figures":"Net Sales: 64,800 hundred million yen\nOperating Income: 2,400 million yen\nOrdinary Income: 1,800 million yen\nNet Income Attributable to Owners of Parent: 1,500 million yen\nNet Income per Share: 175.73 yen\nYear-end Dividend: 46 yen\/ shares\nAnnual Dividend: 91 yen\/ shares","jir_meta_title":"Fuso Pharmaceutical Industries,Ltd. \u2014 Revision of Earnings Guidance and Year-end Dividend Forecast\uff5cFY ending March 2027","jir_meta_description":"Fuso Pharmaceutical Industries,Ltd. has upwardly revised its full-year earnings guidance for the fiscal year ending March 2027 and increased the year-end dividend to 46 yen. Net sales are expected at 64,800 hundred million yen and the annual dividend at 91 yen. Balancing investments to strengthen stable supply and shareholder returns remains a key priority.","jir_og_title":"Fuso Pharmaceutical Industries,Ltd. Announces Earnings Guidance Revision and Dividend Increase","jir_og_description":"Fuso Pharmaceutical Industries,Ltd. has upwardly revised its FY ending March 2027 earnings guidance and raised the year-end dividend to 46 yen, with an expected annual dividend of 91 yen. The announcement also outlines future investment and shareholder return policies.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57749,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-149177","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n